Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses

8 Dec 2020

Abstract excerpt

Immunocytokines hold great potential as anticancer agents, as they use a specific antitumor antibody to deliver an immune-activating cytokine directly to the immunosuppressive tumor microenvironment (TME). We have developed a novel immunocytokine (KD033) composed of a fully human, high-affinity antiprogrammed death-ligand 1 (PD-L1) linked to the sushi-domain of the human IL-15/IL-15 receptor alpha (IL-15/IL-15Rα)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33293344
DOI: 10.1158/1535-7163.mct-20-0457

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory ResponsesPMID 33293344Read ↗

Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicitySemantic proximity Read ↗

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsSemantic proximity Read ↗

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophagesSemantic proximity Read ↗

A novel immunogene therapy to cancer with high tumor selectivity and safetySemantic proximity Read ↗

Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of LymphodepletionSemantic proximity Read ↗

Therapeutic potential of interleukin‑15 in cancer (Review)Semantic proximity Read ↗

Combination strategies with PD-1/PD-L1 blockade: current advances and future directionsSemantic proximity Read ↗

Interleukin-15-armored GPC3-CAR T cells for patients with solid cancersSemantic proximity Read ↗

NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor controlSemantic proximity Read ↗

Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15Semantic proximity Read ↗

Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemiaSemantic proximity Read ↗

NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.